The United States Food and Drug Administration (US FDA) inspected Company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad, from 4th to 13th November 2019. At the end of the inspection, we have been issued a 'Form 483' with 14 observations. We believe that none of these observations are related to data integrity issues. The Company will respond to the US FDA within the stipulated timeline.
Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.433.4 as compared to the previous close of Rs. 437.6. The total number of shares traded during the day was 375781 in over 6214 trades.
The stock hit an intraday high of Rs. 457.6 and intraday low of 427.65. The net turnover during the day was Rs. 165787942.